| 前收盘价格 | 9.21 |
| 收盘价格 | 9.30 |
| 成交量 | 1,718,579 |
| 平均成交量 (3个月) | 2,144,771 |
| 市值 | 708,479,744 |
| 价格/销量 (P/S) | 1.80 |
| 股市价格/股市净资产 (P/B) | 1.12 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2025 |
| 营业毛利率 | -10.92% |
| 营业利益率 (TTM) | 37.82% |
| 稀释每股收益 (EPS TTM) | -0.660 |
| 季度收入增长率 (YOY) | 646.20% |
| 总债务/股东权益 (D/E MRQ) | 1.59% |
| 流动比率 (MRQ) | 4.58 |
| 营业现金流 (OCF TTM) | -250.70 M |
| 杠杆自由现金流 (LFCF TTM) | -2.69 M |
| 资产报酬率 (ROA TTM) | -5.39% |
| 股东权益报酬率 (ROE TTM) | -7.34% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Arvinas, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
0.5
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.50 |
|
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 6.89% |
| 机构持股比例 | 90.98% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 16.00 (Barclays, 65.80%) | 购买 |
| 中 | 14.00 (45.08%) | |
| 低 | 6.00 (Goldman Sachs, -37.82%) | 卖出 |
| 平均值 | 13.00 (34.72%) | |
| 总计 | 4 购买, 1 卖出 | |
| 平均价格@调整类型 | 9.25 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Barclays | 06 Nov 2025 | 16.00 (65.80%) | 购买 | 9.57 |
| 17 Sep 2025 | 16.00 (65.80%) | 购买 | 7.61 | |
| Wells Fargo | 06 Nov 2025 | 15.00 (55.44%) | 购买 | 9.57 |
| BTIG | 30 Oct 2025 | 14.00 (45.08%) | 购买 | 9.93 |
| 18 Sep 2025 | 10.00 (3.63%) | 购买 | 7.72 | |
| Goldman Sachs | 15 Oct 2025 | 6.00 (-37.82%) | 卖出 | 9.46 |
| Stephens & Co. | 18 Sep 2025 | 14.00 (45.08%) | 购买 | 7.72 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合